



COMPANY OVERVIEW

Amarantus BioScience Holdings, Inc. is a publicly traded biotechnology company focused on developing therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology.

RECENT NEWS

Amarantus Announces Positive Pre-Clinical Data for MANF in Wolfram Syndrome Presented at the 79th Annual Scientific Sessions of the American Diabetes Association

Jun 18 2019, 8:00 AM EDT

Amarantus Announces Issuance of US Patent No. 10,195,251 Covering MANF Treatment of Wolfram's Syndrome, Retinitis Pigmentosa, and Glaucoma for Subsidiary MANF Therapeutics

Jun 13 2019, 8:42 AM EDT

Amarantus to Present at 9th Annual LD Micro Invitational Conference

Jun 4 2019, 1:39 PM EDT

STOCK OVERVIEW

Symbol	AMBS
Exchange	OTCPink
Shares OS	68,272,000
Market Cap	\$1.37M
Last Price	\$0.02
52-Week Range	\$0.0151 - \$0.0765
Fiscal Year End	December 31

INVESTOR RELATIONS

American Capital Ventures, Inc.
Howard Gostfrand
President
T: 305-918-7000
F: 305-468-6165
hg@amcapventures.com

06/20/2019 03:40 PM EDT

MANAGEMENT TEAM

Gerald E. Commissiong
President & Chief Executive Officer

Brian E. Harvey, MD, PhD
Chief Regulatory Advisor

Elise Brownell, Ph.D.
Senior Vice President of Operations and Project Management

John W. Commissiong, PhD
Chief Scientific Officer

Paula Trzepacz, MD
Chief Medical Advisor to Elto Pharma

Dr. Richard Kagan
Chief Medical Advisor to Cutanogen Corporation

Michael T. Ropacki, PhD
Chief Medical Advisor - Alzheimer's Blood Diagnostic LymPro Test®

AMARANTUS BIOSCIENCE HOLDINGS, INC.

45 Wall Street
Suite 920
New York, NY 10005
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.